<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04267016</url>
  </required_header>
  <id_info>
    <org_study_id>TGRP01-US001</org_study_id>
    <nct_id>NCT04267016</nct_id>
  </id_info>
  <brief_title>Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care</brief_title>
  <official_title>A Clinical Pilot Study to Test the Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transplant Genomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Transplant Genomics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study in renal transplant recipients to evaluate the acceptability,&#xD;
      feasibility, and clinical utility of TruGraf® testing in conjunction with standard clinical&#xD;
      assessment. TruGraf is the first and only non-invasive test approved by Medicare to rule out&#xD;
      silent rejection in stable kidney transplant recipients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision to cancel study&#xD;
  </why_stopped>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Actual">May 11, 2021</completion_date>
  <primary_completion_date type="Actual">May 11, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Utility of TruGraf Results</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Percent of total number of TruGraf results that the PI identified as having clinical utility</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of TruGraf Results</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Percent of total number of TruGraf results that the PI identified as being correlated to other clinical results obtained through the standard of care.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of TruGraf Testing</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Percent of total number of eligible subjects for whom the PI was able to complete the entire TruGraf testing workflow</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">26</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>All Subjects Enrolled</arm_group_label>
    <description>Renal transplant recipients who are undergoing routine management</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>TruGraf Testing - Peripheral blood gene expression profiling</intervention_name>
    <description>5 mL collection PAXgene blood sample</description>
    <arm_group_label>All Subjects Enrolled</arm_group_label>
    <other_name>Standard of care</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All eligible renal transplant recipients who meet the inclusion/exclusion criteria will be&#xD;
        part of this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recipient of a primary or subsequent deceased-donor or living donor kidney&#xD;
             transplantation.&#xD;
&#xD;
          -  Stable serum creatinine (current serum creatinine &lt;2.3 mg/dl, &lt;20% increase compared&#xD;
             to the average of the previous 3 serum creatinine levels)&#xD;
&#xD;
          -  Kidney transplant patients who &gt;90 days (+/- 2 weeks) post-transplant will be included&#xD;
             in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Need for combined organ transplantation with an extra-renal organ and/or islet cell&#xD;
             transplant.&#xD;
&#xD;
          -  Recipients of previous non-renal solid organ and/or islet cell transplantation.&#xD;
&#xD;
          -  Infection with HIV.&#xD;
&#xD;
          -  Infection with BK nephropathy.&#xD;
&#xD;
          -  Patients that have nephrotic proteinuria (urine protein &gt;3 gm/day).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Patty West-Thielke, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Transplant Genomics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Marsh CL, Kurian SM, Rice JC, Whisenant TC, David J, Rose S, Schieve C, Lee D, Case J, Barrick B, Peddi VR, Mannon RB, Knight R, Maluf D, Mandelbrot D, Patel A, Friedewald JJ, Abecassis MM, First MR. Application of TruGraf v1: A Novel Molecular Biomarker for Managing Kidney Transplant Recipients With Stable Renal Function. Transplant Proc. 2019 Apr;51(3):722-728. doi: 10.1016/j.transproceed.2019.01.054. Epub 2019 Jan 26.</citation>
    <PMID>30979456</PMID>
  </reference>
  <reference>
    <citation>First MR, Peddi VR, Mannon R, Knight R, Marsh CL, Kurian SM, Rice JC, Maluf D, Mandelbrot D, Patel A, David J, Schieve C, Lee D, Lewis P, Friedewald JJ, Abecassis MM, Rose S. Investigator Assessment of the Utility of the TruGraf Molecular Diagnostic Test in Clinical Practice. Transplant Proc. 2019 Apr;51(3):729-733. doi: 10.1016/j.transproceed.2018.10.024. Epub 2018 Dec 11.</citation>
    <PMID>30979457</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

